ENXTPA:NANOBiotechs
Nanobiotix Lung Cancer Trial Data Support Re Rating And Key Catalysts
Nanobiotix reported first clinical data from the Johnson & Johnson sponsored Phase 2 CONVERGE trial of JNJ-1900 (NBTXR3) in stage 3 inoperable non small cell lung cancer.
Results presented at a major conference showed initial signals of efficacy alongside an acceptable safety profile.
The data mark the first readout from a pivotal trial of Nanobiotix’s lead asset in this lung cancer setting.
For investors watching ENXTPA:NANO, this update lands after a period of strong share price...